Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Globe Newswire•31/07/2026•08:10 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.